SPINK5抗体;SPINK5 Antibody—艾普蒂

+ +

•  

   

     IHC-P analysis of esophagus tissue by SPINK5 antibody (P15525) IHC-P was performed using sections of the formalin-fixed paraffin-embedded esophagus tissue;Result: Squamous epithelial cells are positively stained at the cytoplasm.    

  
  

SPINK5 antibodies target the serine protease inhibitor Kazal-type 5 (SPINK5) protein, also known as LEKTI (lympho-epithelial Kazal-type-related inhibitor). SPINK5 is a key regulatory protein encoded by the SPINK5 gene, primarily expressed in epithelial tissues like the skin, thymus, and mucous membranes. It plays a critical role in maintaining skin barrier integrity by inhibiting proteolytic enzymes, particularly kallikrein-related peptidases (KLKs), which regulate desquamation and inflammation. Dysregulation of SPINK5/LEKTI due to genetic mutations is linked to Netherton syndrome, a severe autosomal recessive disorder characterized by defective skin barrier function, chronic inflammation, and allergic manifestations.

Antibodies against SPINK5 are essential tools in research and diagnostics. They help quantify LEKTI expression levels in tissues or biological fluids, aiding in the identification of Netherton syndrome and related skin disorders. Additionally, these antibodies are used to study the molecular mechanisms underlying epidermal homeostasis, inflammation, and protease-antiprotease imbalances. In clinical contexts, SPINK5 antibodies may assist in evaluating therapeutic interventions aimed at restoring skin barrier function or modulating protease activity. Their development has also contributed to understanding broader roles of SPINK5 in immune regulation and its potential involvement in allergic diseases. Research continues to explore SPINK5-targeted therapies and biomarkers for personalized treatment approaches.